Funding Opportunities 24 July 2017

TO:                  Faculty and Staff

FROM:            The Research Office and the Office of Sponsored Research and Programs

SUBJECT:       Funding Opportunities 24 July 2017

All applications developed in response to a funding announcement are to be routed through the Office of Sponsored Research and Programs (OSRP) for university approval before being released to the external agency. Please inform us of your intent to submit as soon as you know you plan to apply and at least 30 days prior to the due date. 

When there is a limit on the number of proposals that may be submitted for a solicitation, to ensure that the university submits the most competitive proposal, an internal review and selection process will be implemented. Please inform us of your intent to submit as soon as you know you plan to apply and at least 6 weeks prior to the due date or you may miss the internal selection deadline.  

Please send notifications to sdudley@uncfsu.edu and information will be provided on the submission procedures and timelines.

Dr. Daryush Ila, Associate Vice Chancellor for Research, Tech Transfer Officer & RSO dila@uncfsu.edu x 2417
Dr. Leslie Evelyn, Director of Sponsored Research and  Programs, aevelyn@uncfsu.edu x 1644
Shenetta Dudley, Pre-Award Administrator sdudley@uncfsu.edu x1570
Carolyn Harris, Post Award Administrator charri35@uncfsu.edu x 2612
Dwane Hodges, Budget Officer dhodges1@uncfsu.edu x 1645
Dr. Carla Raineri Padilla, Compliance & Export Control Officer, cpadilla@uncfsu.edu x 1569 

International Research Collaboration on Alcohol and Alcoholism
PAR-14-268
Synopsis: This Funding Opportunity Announcement (FOA) invites applications for the purpose of fostering international collaborations between alcohol research investigators within the United States and investigators located at non-United States laboratories and performance sites for the mutual advancement of our understanding of alcohol problems and of clinical and public health approaches to their solutions. The program is intended to provide funds for research activities to be undertaken jointly between the U.S. and non-U.S. laboratory that expands the research direction of both the U.S. and non-U.S. laboratories in a collaborative manner.

Eligible Institutions:  Historically Black Colleges and Universities
Closing Date:             7 Sept 2017
Program Funding:        Discretionary
Award Ceiling:             $250,000
Award Floor:                none listed
Instrument Type:          Grant
Cost Sharing/Matching:  NO

Link to the Solicitation: http://grants.nih.gov/grants/guide/pa-files/PAR-14-268.html
Agency:  NIH 

Small Grants on Primary Immunodeficiency Diseases
PAR-17-332
Synopsis: This Funding Opportunity Announcement (FOA) will support small grants on primary immunodeficiency diseases focusing on ex vivo studies with human specimens and on studies with current or new animal models including novel clinical strategies for detecting, identifying the molecular basis of, or developing innovative therapies for primary immunodeficiency diseases. In addition, this FOA aims to encourage analyses of clinical data and samples maintained in primary immunodeficiency registries, consortium databases and repositories to address questions relevant to primary immunodeficiency research. The R03 grant supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. The R03 is intended to support small research projects that can be carried out in a short period of time with limited resources. Investigators who have not received independent NIH funding or independent NIH funding in this field are encouraged to apply to this FOA.

Eligible Institutions:       Historically Black Colleges and Universities
Closing Date:                  Next Cycle- 16 October 2017
Program Funding:             Discretionary
Award Ceiling:                  $50,000
Award Floor:                     none listed
Instrument Type:               Grant
Cost Sharing/Matching:  NO 

DoD Epilepsy Idea Development Award
W81XWH-17-ERP-IDA
Synopsis: The ERP Idea Development Award (IDA) mechanism was first offered in FY15. Since then, 64 IDA applications have been received, and 11 have been recommended for funding. The intent of the FY17 ERP IDA is to solicit research to understand the magnitude and underlying mechanisms of PTE. The FY17 ERP IDA offers two levels of funding. Funding Level I is intended to support high-risk or high-gain research from Principal Investigators (PIs) at or above the level of a postdoctoral fellow (or equivalent), but below the level of Assistant Professor (or equivalent). Note that PIs submitting Funding Level I applications will be required to verify their eligibility for this award. Funding Level II is intended to support a more mature, hypothesis-driven research project. To be considered for an FY17 ERP IDA Funding Level II, the PI must be an independent investigator at or above the level of Assistant Professor (or equivalent). While not required, applications to either Funding Level I or II should provide relevant preliminary data. Preliminary data for either Funding Level may come from the PI’s published work, pilot data, or from peer-reviewed literature. The requested budget level should be appropriate for the scope of research proposed. For Funding Level I: The anticipated direct costs budgeted for the entire period of performance for an FY17 ERP IDA award will not exceed $300,000. The maximum period of performance is 2 years. Refer to Section II.D.5, Funding Restrictions, for detailed funding information. For Funding Level II: The anticipated direct costs budgeted for the entire period of performance for an FY17 ERP IDA award will not exceed $500,000. The maximum period of performance is 3 years. Refer to Section II.D.5, Funding Restrictions, for detailed funding information. FY17 ERP IDA Focus Areas: The research impact for the FY17 ERP IDA is expected to benefit the military, Veteran, and civilian communities. To this end, applications should address at least one of the following FY17 ERP IDA Focus Areas. An application that proposes research outside of these FY17 ERP IDA Focus Areas is acceptable, as long as the applicant provides a strong rationale. These should be carefully considered as part of the application process.

  • Epidemiology: Epidemiological characterization of PTE following TBI, which may include: ○ Risk factors such as demographics, genetic factors, organic head injury factors, or type of insult ○ Differentiation of PTE and psychogenic non-epileptic seizures (PNES)

○ Outcomes including latency to epilepsy, morbidities and comorbidities, and mortality

○ Pre-existing conditions including psychological and psychiatric risk factors Note: Applications proposing epidemiological research should be submitted under the Epidemiology Option.

  • Markers and Mechanisms: Identifying markers or mechanisms (via clinical prospective or preclinical models) that address PTE:

○ Early detection

○ Diagnosis

○ Prognosis

○ Morbidity

○ Comorbidity

○ Mortality ○ Risk stratification

  • Models of PTE: Development of new models or better characterization of existing etiologically relevant models for PTE, including repetitive TBI.
  • Psychogenic Non-Epileptic Seizures: Exploration of the epidemiology, mechanisms, risk factors, or markers of PNES subsequent to TBI.

Note: Research focusing on interventional clinical trials (e.g., pharmacological interventions) is strongly discouraged.

Eligible Institutions:  Unrestricted
Closing Date:             20 Sept 2017
Program Funding:        $4,800,000
Award Ceiling:             none listed
Award Floor:                none listed
Instrument Type:          Grant
Cost Sharing/Matching:  No

Link to the Solicitation: https://www.grants.gov/web/grants/view-opportunity.html?oppId=29575
Agency:  Dept of the Army—USAMRAA 

DoD Peer Reviewed Alzheimer’s Research
W81XH-17-PRARP-CSRA
Synopsis:
The PRARP Convergence Science Research Award (CSRA) mechanism was first offered in FY12. Since then, 195 CSRA applications have been received, and 36 have been recommended for funding. The intent of the FY17 PRARP CSRA is to support efforts to generate research resources, tools, or novel research efforts for researchers and/or practitioners in health sciences related to the PRARP’s mission (see Section II.A, Program Description). The FY17 PRARP CSRA is open to Principal Investigators (PIs) at or above the level of Assistant Professor (or equivalent) from any field or discipline. As part of the application, the PI should demonstrate that the study team has experience in both TBI and AD/ADRD research. Preliminary data, while not required, are encouraged. Preliminary data may come from the PI’s published work, pilot data, or from peer-reviewed literature. The anticipated direct costs budgeted for the entire period of performance for an FY17 PRARP CSRA will not exceed $500,000. The maximum period of performance is 3 years. Refer to Section II.D.5, Funding Restrictions, for detailed funding information. The research impact is expected to benefit the military, Veteran, and civilian communities. To this end, the PRARP has identified CSRA Overarching Challenges and Focus Areas by which the intent of this mechanism can be facilitated. These should be carefully considered as part of the application process. FY17 PRARP CSRA Overarching Challenges: This FY17 PRARP CSRA funding opportunity requires applications to address one or more of the following FY17 PRARP CSRA Overarching Challenges:

  • Paucity of Research Resources: The paucity of research resources to examine the interrelationship between TBI and subsequent AD/ADRD for the military, Veteran, and civilian communities.
  • Paucity of Clinical Studies: The paucity of clinical studies to examine the interrelationship between TBI and subsequent AD/ADRD for the military, Veteran, and civilian communities. This includes research into risk factors that may predispose individuals to AD/ADRD subsequent to TBI.
  • Diagnostic Technologies, Tests, Biomarkers or Devices: The need for technologies, tests, or devices to detect or prognose the progression to AD/ADRD subsequent to TBI. This includes research into risk factors that may predispose individuals to AD/ADRD subsequent to TBI.
  • Epidemiology: The paucity of epidemiological research to examine the interrelationship between TBI and subsequent AD/ADRD for the military, Veteran, and civilian communities. This includes research into risk factors that may predispose individuals to AD/ADRD subsequent to TBI. FY17 PRARP CSRA Focus Areas: In addition to addressing one or more of the specified FY17 PRARP CSRA Overarching Challenges, applications should address at least one of the following FY17 PRARP CSRA Focus Areas in support of the FY17 PRARP CSRA Overarching Challenges. An application that proposes research outside of the FY17 PRARP CSRA Focus Areas is acceptable, as long as the applicant provides a strong rationale:
  • Genomics/Proteomics: Studies or technologies (e.g., genetic, proteomic, bioinformatics and epigenetic strategies) intended to characterize neurological change(s) associated with TBI and subsequent AD/ADRD. In addition, relevant technologies or tests may be considered under this focus area.
  • Mechanisms of Pathogenesis: Identification of contributing mechanisms (e.g., pathology of Tau, non-neuronal cells, inflammatory factors, and vascular contributions) associated with TBI and subsequent AD/ADRD pathogenesis. Biomarkers: Development of strategies to diagnose, prognose, or characterize neurological changes or risk factors associated with TBI and subsequent AD/ADRD (e.g., fluid-based, imaging, physiological, and clinical approaches).
  • Novel Target Identification: Basic research (non-human) directly leading to identification of new targets for the development of existing or new investigational medicines, drugs, or agents.
  • Epidemiological Research: Research focusing on the incidence, distribution, and other factors relating to the health of individuals affected by TBI and subsequent AD/ADRD. The following is specifically discouraged under the FY17 PRARP:
  • Pharmacological Interventions.

Eligible Institutions:  Unrestricted
Closing Date:             20 Sept 2017
Program Funding:       $3,800,000
Award Ceiling:            none listed
Award Floor:               none listed
Instrument Type:         Grant
Cost Sharing/Matching:  No

Link to the Solicitation: https://www.grants.gov/web/grants/view-opportunity.html?oppId=295757
Agency:  Dept of the Army– USAMRAA